Previous 10 | Next 10 |
Gainers: [[VIVO]] +6%. [[ABUS]] +4.6%. [[AY]] +4.2%. [[EBON]] +3.5%. [[TSE]] +3.4%.Losers: [[ACLS]] -14%. [[DOGZ]] -8.5%. [[HX]] -7.8%. [[FIXX]] -5.9%. [[JRJC]] -2.1%. For further details see: AY, ABUS, ACLS and FIXX among after-hours movers
Are These On Your List Of Penny Stocks To Buy Right Now? One of the things we’ve discussed when it comes to penny stocks is price. Obviously, we’re talking about stocks under $5 overall. But the lower the price, typically, the higher the volatility and quicker the ...
WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (includin...
Penny Stocks To Buy According To These 3 Analysts Here we are, the final few weeks of 2020 and of course, we’re looking for top penny stocks to watch right now. Whether you’ve been watching on the sidelines are “getting into the game” the stock market has...
Gainers: [[MREO]] +37.1%. [[BW]] +9.1%. [[ABUS]] +6.1%. [[CLNY]] +5.1%. [[MVIS]] +4.4%.Losers: [[SCPS]] -22.7%. [[SCHL]] -13%. [[SCS]] -7.3%. [[AIR]] -6.8%. [[X]] -5.1%. For further details see: X, CLNY, MVIS and AIR among after-hours movers
Arbutus Biopharma ([[ABUS]] +3.4%) was initiated with a Buy rating at H.C. Wainwright, PT $10.Analyst Ed Arce mentions that company is unique as an hepatitis B virus pure-play given that its management has designed and assembled a broad, proprietary portfolio.He further sees momentum building...
Takung Art (TKAT) +81%.Evolus (EOLS) +43% after company updates on U.S. ITC case related to Jeuveau sales and marketing.Skillful Craftsman Education Technology (EDTK) +17%.Marathon Patent Group (MARA) +23%.Rite Aid Corporation (RAD) +21% on Q3 results.Vivos Therapeuti...
Palm Beach, FL – December 15, 2020 – While the pharmaceutical industry has had an amazing record of developing therapeutic drugs for countless uses, sometimes, a remaining part of the problem is how do you get the drug into the patient’s body? The simplest way is usuall...
vTv Therapeutics VTVT +128% as MacAndrews & Forbes buys 625K shares.Sonoma Pharmaceuticals SNOA +122% on Crown Laboratories partnership.FAT Brands FAT +60% on plan to merge with controlling shareholder Fog Cutter Capital.Lexicon Pharmaceuticals LXRX +38%...
Arbutus Biopharma (ABUS) announces additional data from an ongoing Phase 1a/1b trial, AB-729-001, evaluating AB-729, its proprietary GalNAc delivered RNAi compound, for Chronic Hepatitis B virus infection.Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg (surface antigen...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...